NCT00883415

Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease

A Study to Evaluate the Effect of the Treatment of Anemia on Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 20 (actual)
• Sponsor: University of Maryland, Baltimore · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study examines patients with chronic kidney disease-related anemia and measures changes in the metabolism of the heart using FDG/PET scanning, before and 6 months after their health-care provider has initiated anemia management therapy with the FDA-approved drug darbepoetin alfa (Aranesp), which is approved for chronic kidney disease-related anemia. The investigators hypothesize that the heart has abnormal metabolism with the anemia of chronic kidney disease but this improves after correction of this anemia with darbepoetin alfa.

Conditions

• Cardiomyopathy
• Chronic Kidney Disease
• Anemia

Interventions

Type	Name	Description
DRUG	Darbepoetin alfa	Subjects will undergo anemia management with darbepoetin after baseline assessment of MGU and will continue for six months with repeat assessment of MGU at completion of protocol

Timeline

• Start date: 2008-05-01
• Primary completion: 2012-11-01
• Completion: 2012-11-01
• First posted: 2009-04-17
• Last updated: 2020-05-21
• Results posted: 2020-05-21

Locations

1 site across 1 country: United States